Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of application of pharmaceutical composition

A composition and medicine technology, applied in the field of medicine, can solve the problems of improper treatment, non-alcoholic fatty liver disease, lack of medical treatment and lack of medicine for obesity, and achieve the effects of reducing the degree of fatization, promoting the influx of calcium ions, and alleviating pain.

Active Publication Date: 2021-02-05
HUAZHONG UNIV OF SCI & TECH
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Aiming at the defects of the prior art, the present invention provides an active ingredient containing polypeptides extracted from leguminous plants such as soybeans and peas as a pharmaceutical composition, which solves the lack of medical treatment for non-alcoholic fatty liver and obesity in the prior art. Under-drug and inappropriate treatment issues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of application of pharmaceutical composition
  • A kind of application of pharmaceutical composition
  • A kind of application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Peptides Reduce Fat Content and Hepatic Fatty Degree Test

[0028] Establishment of male C57BL / 6 mice (Chow group) fed with normal diet and male C57BL / 6 mice (HFD+Vg group) treated with high-fat diet (High-fat polypeptide) to study non-alcoholic fatty liver experimental animal model .

[0029] Two-month-old male C57BL / 6 mice were randomly divided into three groups: fed with normal diet (Chow group), fed with high-fat diet (HFD) (HFD group) and fed with high-fat diet at the same time Peptide administration treatment (HFD+Vg group). The Chow group was fed with normal feed throughout the experiment, the HDF group and the HFD+Vg group were fed with high-fat feed for 3 months, and then the HFD group continued to be fed with high-fat feed for 5 months, while the HFD+Vg group was fed with high-fat feed. At the same time, oral gavage (20mg / kg) of polypeptide was used every day for 5 months.

[0030] The degree of fatty liver tissue in non-alcoholic fatty liver is ...

Embodiment 2

[0031] Embodiment 2: The test that polypeptide improves insulin resistance

[0032] The pathogenesis of non-alcoholic fatty liver disease is: at the beginning of the disease, lipids accumulate in liver cells, and the phenomenon of fat accumulation is often more likely to occur in patients with type 2 diabetes and other metabolic syndromes; then, insulin resistance and accompanying The inflammation of the liver will further aggravate the symptoms of non-alcoholic fatty liver, and eventually lead to the generation and aggravation of non-alcoholic fatty liver. Insulin resistance refers to the decline in the efficiency of insulin in promoting glucose uptake and utilization due to various reasons, and the body compensatoryly secretes excessive insulin to produce hyperinsulinemia in order to maintain the stability of blood sugar. Since dyslipidemia can stimulate gluconeogenesis, leading to hepatic insulin resistance and decreased peripheral glucose utilization, improving blood lipid...

Embodiment 3

[0036] Embodiment 3: The test that polypeptide reduces alanine aminotransferase ALT and aspartate aminotransferase AST

[0037] ALT and AST are mainly distributed in the hepatocytes of the liver. When the liver cells are in a damaged environment such as inflammation or virus infection, ALT and AST will increase. The extent of its increase is consistent with the extent of liver cell damage, so it is currently the most commonly used liver function index, and ALT and AST are generally elevated in patients with non-alcoholic fatty liver disease. In the experiment, it was found that the ALT and AST of obese non-alcoholic fatty liver mice fed with high-fat diet were significantly increased, and after intragastric administration of polypeptides, the contents of ALT and AST decreased.

[0038] The alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the venous blood of mice with non-alcoholic fatty liver disease decreased significantly after polypeptide administratio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a pharmaceutical composition, the active ingredient of which is at least one of four polypeptides isolated and extracted from soybean or pea, and these four polypeptides can significantly reduce triglyceride, alanine aminotransferase ALT and aspartate aminotransferase AST levels, while reducing fat content and liver fat in patients with non-alcoholic fatty liver disease, improving insulin resistance. The composition is applied to prevent and treat non-alcoholic fatty liver and obesity medicine and health food.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to the application of four polypeptides in the preparation of medicines for preventing and treating non-alcoholic fatty liver and obesity. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver disease caused by a variety of reasons, mainly manifested as abnormal excessive deposition of lipids with triglyceride as the main component in liver cells, and its disease spectrum includes simple fatty liver , steatohepatitis, fatty liver fibrosis and cirrhosis. According to statistics, the incidence rate of non-alcoholic fatty liver in western developed countries is about 30%, while in Asian countries the incidence rate reaches more than 40%, and the incidence rate in obese patients and type 2 diabetes patients is as high as 90%. The pathogenesis of NAFLD is currently more recognized as the "two-hit" theory. The first hit is insulin resis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/16A61P3/06A61P1/16A61P3/04
CPCA23V2002/00A61K38/168A23L33/18A61K2300/00A23V2200/30A23V2200/332
Inventor 陈正望童宇星陈威姜华
Owner HUAZHONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com